Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Income towards Parent Company: 2013-2024

Historic Income towards Parent Company for vTv Therapeutics (VTVT) over the last 12 years, with Dec 2024 value amounting to -$22.7 million.

  • vTv Therapeutics' Income towards Parent Company fell 77.14% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 24.97%. This contributed to the annual value of -$22.7 million for FY2024, which is 12.56% up from last year.
  • Latest data reveals that vTv Therapeutics reported Income towards Parent Company of -$22.7 million as of FY2024, which was up 12.56% from -$26.0 million recorded in FY2023.
  • vTv Therapeutics' Income towards Parent Company's 5-year high stood at -$12.8 million during FY2020, with a 5-year trough of -$26.0 million in FY2023.
  • Its 3-year average for Income towards Parent Company is -$24.6 million, with a median of -$25.1 million in 2022.
  • In the last 5 years, vTv Therapeutics' Income towards Parent Company soared by 41.64% in 2020 and then tumbled by 41.41% in 2022.
  • Over the past 5 years, vTv Therapeutics' Income towards Parent Company (Yearly) stood at -$12.8 million in 2020, then crashed by 38.50% to -$17.7 million in 2021, then plummeted by 41.41% to -$25.1 million in 2022, then dropped by 3.56% to -$26.0 million in 2023, then increased by 12.56% to -$22.7 million in 2024.